IDEMIA
5.10.2020 18:21:12 CEST | Business Wire | Press release
A world first, remote smartphone-based passenger biometric registration gives passengers a smoother and contactless experience from ID registration until they board. Passenger faces - a genuine Open Sesame throughout the airport - are recorded at home on Mona, Lyon Airport’s smartphone app. Having registered in advance, passengers can put their travel documents away as they pass unhindered through the airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005759/en/
Passenger registration is secured by a biometric match between their smartphone-based face and scans of their ID document and boarding card. This totally accurate and reliable identity management system that IDEMIA has perfected lets passengers speed through all identity control points.
RESA’s latest automatic and biometric compact gate dubbed Major eGate , which caters for disabled people too, comes with an integrated camera so that passengers can pass through to the security restricted area and then board their plane based merely on facial recognition.
IDEMIA’s system is universal, secure and works on all airline systems thanks to RESA’s IATA-certified CUPPS system. This will be available at Lyon Airport for Transavia and TAP flights to Portugal.
While this new service is subject to formal CNIL1 approval, to date CNIL has recommended it to safeguard passenger data and rights.
IDEMIA Executive VP Identity and Public Safety Philippe Barreau said: “As biometric security solutions expert, we are thrilled to deliver a world first alongside our customers Vinci Airports and Lyon Airport and our partner RESA. This trial harnesses contactless biometric technology that gives users an unrivaled airport experience without letting up one jot on security. This bears out our capacity to constantly innovate to safeguard passenger trust and help pave the way for even smoother and more secure future travel .”
RESA CEO Renaud Willard said: “Current covid restrictions forced us to rethink how to take care of passengers and their interactions with airport security staff and equipment. The biometric trial underway at Lyon Airport was made possible by French industrial collaboration, whereby hi-tech saved the day despite the current pandemic and economic crisis. We have shown here that passengers can pass through airport checks fully contactless and without handing over paper documents while shoring up security to boot.”
Vinci Airports France & Americas Area Director Valérie Vesque-Jeancard said: “We are thrilled to launch MONA today, a world first, at a time when airports need game-changing innovations so they can give passengers an even safer, more enjoyable and personalized experience. I warmly congratulate all staff involved including IDEMIA and RESA people, who managed to overcome tough restrictions these last few months and deliver a great trial in barely a year.”
IDEMIA provides both rapid and safe passenger flow solutions to countless airports around the world and manages 30-plus government border control programs. In 2017, IDEMIA installed a facial recognition-based biometric ID control system in Terminal 4 of Singapore’s Changi Airport, from baggage check-in right through to aircraft boarding, including going airside and border crossing. The Company has regularly conducted facial recognition technology trials to make boarding smoother.
RESA’s expertise lies in introducing biometric technology to authenticate airport security staff, who need to connect to airport IT systems. RESA is currently engaged in introducing such technology on top of existing passenger airport systems. Previously, the firm has conducted several pilot tests including in Singapore and Paris airports.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About RESA
Backed by 30 years of experience and 1,000-plus software programs installed in 62 countries, RESA is one of the world’s top airport and airline systems developers.
The firm is an innovative Vendée-based small business that develops, sells and maintains a broad range of integrated software covering all airport system needs, including passenger check-in and boarding, baggage tracing and reconciliation, passenger tracking, automatic gates, self-service kiosks and biometrics, flight management, resource allocation, billing, statistics, business intelligence and messaging.
__________________________________
1
France’s national authority responsible for data privacy
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005759/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
